The global hyperkalemia treatment market is divided into North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa based on geography. During the projected period, North America is expected to dominate the worldwide hyperkalemia treatment market, followed by Europe.
Because of advancements in healthcare infrastructure and citizens' unhealthy lifestyles, the United States enjoys a leading position in the North American market. As the incidence of hyperkalemia has been observed to range from 2.6 percent to 3.2 percent, this region has the highest rate of hyperkalemia among others.
Furthermore, due to an increase in drug launches for the treatment of hyperkalemia, the Asia Pacific hyperkalemia treatment market is predicted to rise significantly. In May 2018, the United States Food and Drug Administration (US FDA) approved AstraZeneca's Lokelma, an oral solution of insoluble, non-absorbed sodium zirconium silicate that serves as a highly-selective potassium-removing agent for the treatment of hyperkalemia in adults.
Click here for Hyperkalemia Treatment Market Report: